Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc.

Slides:



Advertisements
Similar presentations
Re-testing for Chlamydia trachomatis Infection in Massachusetts Family Planning Clinics Marie E. Caggiano, William G. Dumas, Thomas E. Bertrand, Katherine.
Advertisements

Effort to Initiate a Chlamydia Prevalence Study within a Managed Care Organization in Philadelphia Pamela G. Nathanson, Dorothy Mann Family Planning Council,
Repeat Infections among Adolescents and Young Adults: Findings From Philadelphia STD Clinics Nicole Liddon, PhD 1 Michael Eberhart, BS 2 Jami Leichliter,
Assessment of Chlamydia Rescreening Practices Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
How to Measure the Effectiveness of the IPP (and all the CT Screening being done)? **Reduce Infertility** Ultimate Goal Reduce PID Reduce Chlamydia Prevalence.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Self-Collected Vaginal Specimens for the Detection of Multiple STIs in Adolescent Detainees Cynthia M. Holland, M.D., M.P.H., Harold C. Wiesenfeld, M.D.,
The Relationship Between Repeat Infections and Behavioral Risk Factors and Clinician Counseling: Findings from a Philadelphia STD Clinic M. Eberhart 1,
Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.
Epidemiology of Chlamydia in the United States Debra J. Mosure, Ph.D. Division of STD Prevention Centers for Disease Control and Prevention March 8, 2004.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study Maria Trent, MD, MPH.
Chlamydia Sexually Transmitted Disease Surveillance 2000 Division of STD Prevention.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Risk factors for Incident Trichomonas vaginalis among Women Recruited in RESPECT-2, an HIV Prevention Trial D Helms 1, D Mosure 1, T Peterman 1, C Metcalf.
Expedited Partner Therapy in Wisconsin STD Control Section Wisconsin Division of Public Health June 2010.
Screening and Treatment for Gonorrhea and Chlamydia as an HIV Prevention Strategy: Rationale and Implementation Thomas Farley, MD MPH Tulane University.
Evaluation of Gonorrhea Screening in Family Planning Settings: California 2000 CK Kent, M Brammeier, G Bolan, N Casas, M Funabiku, P Blackburn Region IX.
Appropriate CT/GC Screening & Factors to Consider Becky McCoy MSN, RN, CEN STD Nurse Consultant.
Concurrent STD Morbidity in Sexual Contacts to Persons with STD’s: Implications for Patient-Delivered Partner Therapy (PDPT) Joanne Stekler, Laura Bachmann,
STD Knowledge and Practices of New York City Providers Meighan E. Rogers, MPH Bureau of STD Control, NYC DOHMH Region II IPP Meeting, May 31-June 1, 2006.
Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
RTI International is a trade name of Research Triangle Institute Untreated chlamydial infection among adolescents and young adults in Baltimore,
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
Trends in Clinic Visits and Diagnosed C. trachomatis and N. gonorrhoeae Infections Following the Introduction of a Co-Pay in an STD Clinic C. Rietmeijer.
NYMAC - March 2008 Explanation of Maps The maps on these slides were created by NYMAC Work Group 2 during the first funding cycle ( ). The WG wanted.
NYMAC - March 2008 Explanation of Maps The maps on these slides were created by NYMAC Work Group 2 during the first funding cycle ( ). The WG wanted.
Chlamydial Infections in the U.S. Steven J Shapiro CCID/NCSHHSTP/DSTDP/PTB Region I Infertility Prevention Project Wells Beach, Maine June 2, 2009 Disclaimer:
1 TITLE X FAMILY PLANNING/HIV INTEGRATION PROJECT Opt Out Process Michael Brannon M.S. HIV/STD Prevention Program Manager (713)
Epidemiology Center Isotretinoin Survey Allen A. Mitchell, MD Carla M. Van Bennekom, RN, MPH Slone Epidemiology Center At Boston University For presentation.
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
Pilot Study: Re-screening Adolescent and Young Adult Women for Chlamydia Infection Alison Muse NYSDOH Bureau of STD Control Region II IPP meeting November.
Utilization of Cross-matching Databases to Obtain Chlamydia Re-screening and Re-infection Rates for Family Planning/Infertility Prevention Project Clinics:
Region II IPP Data & Infrastructure Performance Measures Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
Kow-Tong Chen, M.D., Ph.D., Hsiao-Ling Chang, Ph.D., Chu-Tzu Chen, M.P.H., and Ying-An Chen, M.P.H. Volume 23, Number 3, 2009 AIDS PATIENT CARE and STDs.
IPP Measures of Effectiveness Utilization of Data to Evaluate and Inform Project Activities December 12, 2007 Kelly Morrison Opdyke, MPH Region II Infertility.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.
Infrastructure Update Jennifer Kawatu Kim Watson Andee Krasner
Targeting Chlamydia Screening Resources Region II IPP Advisory Meeting May 31, 2006 Kelly Opdyke, MPH Cicatelli Associates Inc.
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
Predicting Pregnancy Risk among Women Attending an STD Clinic Judith Shlay MD, MSPH Denver Public Health September 21, 2008 CityMatCH Conference.
Jessica Carag MS Candidate Public Health Microbiology & Emerging Infectious Diseases Milken Institute School of Public Health The George Washington University.
STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
Research objective Annually, around 9 million injured children are treated in U.S. emergency departments. For injuries that require medical care beyond.
NYC DOHMH BSTDC School-Based Education, Screening and Treatment Pilot Program Meighan Rogers, MPH Bureau of STD Control, NYC DOHMH Region II IPP Meeting,
Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.
Transition to the New CDC Recommendations: Putting it into Practice Shelley Miller, MS TRAINING 3, Family Planning Council June 14, 2007 OPA HIV Grantee.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.
HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.
CT and GC Screening: What about the guys?! Gale R Burstein, MD, MPH, FAAP, FSAHM Erie County Department of Health SUNY at Buffalo School of Medicine Buffalo,
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
Check Your Risk: Increasing School-Based STI Screening Participation Among District of Columbia High School Students Michelle Jasczyński, Ed.M. Public.
Associations Between Recent Gender- Based Violence and Pregnancy, Sexually Transmitted Infections, Condom Use Practices, and Negotiation of Sexual Practices.
1University of Kentucky, Lexington, Kentucky
Roland C. Merchant, MD, MPH, ScD
Martin Goldberg1, Daniel R. Newman2, TA Peterman2,
Family Planning & STDP Brainstorming
Can Self-collected Vaginal Swabs Facilitate Testing for Repeat Chlamydia trachomatis Infections among STD Clinic Clients Good morning everyone! I am going.
M Javanbakht, S Guerry, LV Smith, P Kerndt
Region I IPP Data Update Region I IPP Advisory Board Meeting
Treatment Verification Rates for Chlamydia and Gonorrhea
Gonorrhea Screening: What Do the Data Tell Us?
Presentation transcript:

Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc. Mary Dupuis Sammel, ScD and Michelle Berlin, MD, MPH Center for Clinical Epidemiology and Biostatistics University of Pennsylvania Medical Center Philadelphia, PA

Background The Region III Chlamydia Project has provided chlamydia screening and treatment for women as part of CDC’s National Infertility Prevention Program (IPP) since The Region III Chlamydia Project has provided chlamydia screening and treatment for women as part of CDC’s National Infertility Prevention Program (IPP) since All women under age 30 who undergo a pelvic exam are routinely screened for chlamydia in family planning (FP) clinics. All women under age 30 who undergo a pelvic exam are routinely screened for chlamydia in family planning (FP) clinics. Approximately 300,000 women are screened annually throughout the 8 project areas (Baltimore, Delaware, Maryland, Pennsylvania, Philadelphia, Virginia, West Virginia, Washington DC). Approximately 300,000 women are screened annually throughout the 8 project areas (Baltimore, Delaware, Maryland, Pennsylvania, Philadelphia, Virginia, West Virginia, Washington DC).

Screening Program Issues Anecdotal reports from providers suggested high levels of repeat chlamydia infections among women attending family planning clinics. Anecdotal reports from providers suggested high levels of repeat chlamydia infections among women attending family planning clinics. Increased efforts around partner management were initiated, with little concrete data on repeat infection rates. Increased efforts around partner management were initiated, with little concrete data on repeat infection rates. Some providers wanted to avoid repeat screenings of women testing negative on prior visits, but had no data to support this change in screening practices. Some providers wanted to avoid repeat screenings of women testing negative on prior visits, but had no data to support this change in screening practices.

Objectives To determine rates of repeat infections among women screened for chlamydia in family planning clinics in Region III between 1996 and To determine rates of repeat infections among women screened for chlamydia in family planning clinics in Region III between 1996 and To determine if a low-risk group could be identified that might not require repeat screening over time. To determine if a low-risk group could be identified that might not require repeat screening over time.

Methods Analysis was conducted on 174,278 tests performed on 73,107 women from 1996 to 1998 in 6 of 8 project areas (Baltimore, Delaware, Pennsylvania, Philadelphia, Virginia, Washington DC). Analysis was conducted on 174,278 tests performed on 73,107 women from 1996 to 1998 in 6 of 8 project areas (Baltimore, Delaware, Pennsylvania, Philadelphia, Virginia, Washington DC).

Description of Data 990,847 Number of records between ,139 Excluded records from males -161,327 Excluded records from non-family planning clinics -247,698 Excluded records from 2 areas without unique Ids ,683 Records from women with at least 1 visit -354,889 Excluded records with only 1 visit ,794 Records for 85,175 women with multiple visits -22,516 Records with discrepancies (mismatched age, etc.) ,278 Total records for 73,107 women

Methods Positivity rates for women with prior positive chlamydia tests were compared to those for women with prior negative tests. Positivity rates for women with prior positive chlamydia tests were compared to those for women with prior negative tests. Variables in the analysis included: Variables in the analysis included:  age  time since prior visit  project area where patient was tested.

Number of Visits Per Woman # of Visits Frequency% 253, , , , < <0.1 TOTAL73,

Demographic DistributionTOTAL73, % PROJECT AREA NPercent BaltimoreDelawareMarylandPennsylvaniaPhiladelphiaVirginia Washington DC West Virginia 2,0486,218031,92021,58910, %8.5%0.0%43.7%29.5%14.3%1.2%0.0% AGE (years) NPercent ,34623,93922,98214,48710,1231.8%32.8%31.5%19.9%13.9%

Infection Rates by Infection Status at Prior Visit Infected at Prior Visit Uninfected at Prior Visit Rate Ratio OVERALL19.7%3.7%5.4 Baltimore n=2, %3.5%5.9 Delaware n=6, %3.6%3.7 Pennsylvania n=31, %1.8%7.2 Philadelphia n=21, %6.1%4.2 Virginia n=10, %4.1%3.8 Wash DC n= %2.7%3.4

Infection Rates by Infection Status at Prior Visit –By Age Group Infected at Prior Visit Uninfected at Prior Visit RateRatio OVERALL19.7%3.7% – 14 yrs n=1, %8.7% – 19 yrs n=23, %6.0% – 24 yrs n=22, %3.9% – 29 yrs n=14, %2.3% yrs n=10, %1.1%10.8

Infection Rates by Infection Status at Prior Visit and Time Since Prior Visit Infected at Prior Visit Uninfected at Prior Visit RateRatio OVERALL19.7%3.7%5.4 < 10 months 21.5%4.3% months* 12.8%2.6%4.9 > 14 months 13.2%3.8%3.4 *10-14 months analogous to “routine” or annual visit.

Limitations Unable to distinguish between new infections, reinfections, and persistent infections. Unable to distinguish between new infections, reinfections, and persistent infections. Women do not get all of their care at FP clinics, and therefore, we may be missing additional infections diagnosed in other settings. Women do not get all of their care at FP clinics, and therefore, we may be missing additional infections diagnosed in other settings. Many clinics do not use unique identifiers, and therefore patients from those clinic sites are excluded from the analysis. Many clinics do not use unique identifiers, and therefore patients from those clinic sites are excluded from the analysis. Data on clinical signs and risk history are collected inconsistently, and could not be used in the model. Data on clinical signs and risk history are collected inconsistently, and could not be used in the model.

Conclusions Women screened for chlamydia in family planning clinics who have an initial positive test are at high risk for subsequent infection. Women screened for chlamydia in family planning clinics who have an initial positive test are at high risk for subsequent infection. Chlamydia positivity among women previously infected is higher among young women and women from urban areas, reflecting the higher prevalence of disease in these populations. Chlamydia positivity among women previously infected is higher among young women and women from urban areas, reflecting the higher prevalence of disease in these populations. The relative risk of reinfection is greater among women over age 30, perhaps reflecting the higher risk status of women over 30 who are infected at all. The relative risk of reinfection is greater among women over age 30, perhaps reflecting the higher risk status of women over 30 who are infected at all.

Conclusions Chlamydia positivity among women tested less than a year after a previous infection was higher than that of women tested at an annual visit. Chlamydia positivity among women tested less than a year after a previous infection was higher than that of women tested at an annual visit. The relative risk of reinfection was the same for women tested before or at an annual visit, while those tested less often had a lower relative risk of reinfection. The relative risk of reinfection was the same for women tested before or at an annual visit, while those tested less often had a lower relative risk of reinfection.

Implications for the Screening Program Are there high levels of repeat chlamydia infections among women attending family planning clinics? Are there high levels of repeat chlamydia infections among women attending family planning clinics?  Yes – With an overall reinfection rate of 19.7%, the data support the rescreening of women testing positive for chlamydia who return for care in FP clinics. Should providers screen women only once a year? Should providers screen women only once a year?  No – Based on substantial chlamydia positivity among women tested less than 10 months from a prior test, rescreening is warranted even if the next visit is within a year of a prior visit.

Implications for the Screening Program Should providers stop screening women who tested negative on a prior visit? Should providers stop screening women who tested negative on a prior visit?  No - Since chlamydia positivity for women testing negative at a prior visit was greater than 2% overall within the regional screening criteria (age <30), continued screening of all young women attending family planning clinics in Region III is warranted.

Implications for Future Research Since most project areas in Region III have switched to more sensitive amplified testing methods since 1998, this analysis should be performed on more recent data. Since most project areas in Region III have switched to more sensitive amplified testing methods since 1998, this analysis should be performed on more recent data. Future studies of repeat infection may be useful in evaluating current Region III enhanced partner management strategies. Future studies of repeat infection may be useful in evaluating current Region III enhanced partner management strategies.